Soluble amyloid precursor proteins in the cerebrospinal fluid as novel potential biomarkers of Alzheimer's disease: a multicenter study

Item Type:	Article
Title:	Soluble amyloid precursor proteins in the cerebrospinal fluid as novel potential biomarkers of Alzheimer's disease: a multicenter study
Creators Name:	Lewczuk, P. and Kamrowski-Kruck, H. and Peters, O. and Heuser, I. and Jessen, F. and Popp, J. and Buerger, K. and Hampel, H. and Froelich, L. and Wolf, S. and Prinz, B. and Jahn, H. and Luckhaus, C. and Perneczky, R. and Huell, M. and Schroeder, J. and Kessler, H. and Pantel, J. and Gertz, H.J. and Klafki, H.W. and Koelsch, H. and Reulbach, U. and Esselmann, H. and Maler, J.M. and Bibl, M. and Kornhuber, J. and Wiltfang, J.
Abstract:	In this report, we present the results of a multicenter study to test analytic and diagnostic performance of soluble forms of amyloid precursor proteins {alpha} and {beta} (sAPP{alpha} and sAPP{beta}) in the cerebrospinal fluid (CSF) of patients with different forms of dementing conditions. CSF samples were collected from 188 patients with early dementia (mini-mental state examination >or=20 in majority of cases) and mild cognitive impairment (MCI) in 12 gerontopsychiatric centers, and the clinical diagnoses were supported by neurochemical dementia diagnostic (NDD) tools: CSF amyloid{beta} peptides, Tau and phospho-Tau. sAPP{alpha} and sAPP{beta} were measured with multiplexing method based on electrochemiluminescence. sAPP{alpha} and sAPP{beta} CSF concentrations correlated with each other with very high correlation ratio (R=0.96, P<0.001). We observed highly significantly increased sAPP{alpha} and sAPP{beta} CSF concentrations in patients with NDD characteristic for Alzheimer's disease (AD) compared to those with NDD negative results. sAPP{alpha} and sAPP{beta} highly significantly separated patients with AD, whose diagnosis was supported by NDD findings (sAPP{alpha}: cutoff, 117.4 ng ml(-1), sensitivity, 68%, specificity, 85%, P<0.001; sAPP{beta}: cutoff, 181.8 ng ml(-1), sensitivity, 75%, specificity, 85%, P<0.001), from the patients clinically assessed as having other dementias and supported by NDD untypical for AD. We conclude sAPP{alpha} and sAPP{beta} might be regarded as novel promising biomarkers supporting the clinical diagnosis of AD.
Keywords:	Dementia, Alzheimer Disease, Amyloid{beta}, Amyloid Precursor Protein, Multiplexing, Cerebrospinal Fluid
Source:	Molecular Psychiatry
ISSN:	1359-4184
Publisher:	Nature Publishing Group
Volume:	15
Number:	2
Page Range:	138-145
Date:	February 2010
Official Publication:	https://doi.org/10.1038/mp.2008.84
PubMed:	View item in PubMed

Repository Staff Only: item control page